SCOTTSDALE, Ariz., May 11, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI) will host a luncheon press event beginning with a live presentation, conference call and simultaneous webcast for media, investors and analysts in the pharmaceutical, nutraceutical and food engineering industries, followed by one-on-one interviews. The event takes place on June 8 in New York, NY.
Presenting at the event will be Principal Investigator Dr. Smiti Gupta, Assistant Professor of Nutrition and Food Sciences at Wayne State University as well as research collaborator Dr. Fazlul Sarkar, Professor of Pathology at Wayne State School of Medicine and Senior Editor of the Molecular Cancer Therapeutics journal. Also presenting will be company Chief Science Officer Dr. Denis Callewaert, founder of the Center for Biomedical Research at Oakland University, recipient of multiple NIH grants. The scientific panel will be joined by patent counsel Dr. Kenneth Kohn.
The topics covered during this event will include, but are not limited to, the following: HEPI-funded researchers have discovered that, in contrast to the action of statins, isolates from a proprietary HEPI natural product regulate HDL/LDL cholesterol at the genetic level. The isolated molecules are believed to be the only compounds, natural or otherwise, that regulate HDL/LDL in this manner.
The results have been derived from both in vivo and in vitro studies conducted over the past several months and mirror results of an earlier human trial conducted in Cameroon which indicated significant decreases in LDL cholesterol, but were not focused on the method of regulation. That study was published in a peer reviewed journal. A scientific manuscript detailing the results of the current studies is being drafted for review and publication later in the year.
At the event on June 8, researchers will reveal and describe in detail the actual mechanism of regulation. The Company hopes to clearly convey the following key points:
- HEPI has discovered a new way to regulate cholesterol by use of its proprietary isolates
- The HEPI isolates are a natural product that can be introduced into foods and supplements in a very short timeframe
- The HEPI isolates are excellent candidates for drug development, and HEPI principals are exploring relationships with pharmaceutical CRO's and venture partners
- The Company is convening a GRAS panel for evaluation and approval of food safety
The researchers will not reveal the identity, structure or class of compound at this time because additional patent filings are necessary to protect the isolated active molecules.
Reporters wishing to attend the lunch, conference call or webcast, please contact Carla Collado at ccollado@olmsteadwilliams.com or call (310) 824-9000. Analysts and investors, please contact David Sasso at ds@amcapventures.com or call (305) 918-7000.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company engaged in the development of products comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme ® (PAZ™) a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme ®.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
For more information, please visit www.heponline.com/" target="_top" rel="nofollow">http://www.heponline.com.